Ads
related to: life expectancy for myeloma patients symptoms and diagnosis- Treatment Process
Discover The Treatment Info
& View Availability Here.
- Efficacy Data
Review Efficacy, Safety, & Clinical
Trial Data On The HCP Site.
- Treatment Centers
This RRMM Option Is Available
At Certified Treatment Centers.
- Trial Design
Review The Clinical Data For
This RRMM Treatment Option Here.
- Important Safety Info
HCPs: Review Important Safety Info
For This Option In Clinical Trials.
- Nurse Support
Nurses: View The Treatment Journey,
Safety Info, Resources & FAQs Here.
- Treatment Process
Search results
Results From The WOW.Com Content Network
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]
They are less likely than multiple myeloma patients to have lytic bone lesions. In several studies of patients with either form of plasma cell leukemia, the disease was associated with clonal IgG in 28% to 56% of cases, IgA in 4% to 7% of cases, and a light chain in 23% to 44% of cases; 0-12% of patients had no myeloma protein.
Secondary PCL (sPCL) is diagnosed in 1-4% of patients known to have had multiple myeloma for a median time of ~21 months. It is the terminal phase of these patients' myeloma disease. sPCL patients typically are highly symptomatic due to extensive disease with malignant plasma cell infiltrations in, and failures of, not only the bone marrow but also other organs.
Affected individuals may have a somewhat shortened lifespan without treatment. The maximum lifespan without treatment is 67 years. When a 13q deletion is detected, such as in a bone marrow biopsy for Multiple Myeloma, chemo treatments in recent years have the ability to extend life expectancy without limitations depending on response to treatments.
Treatment of patients with this POEMS syndrome variant who have evidence of bone lesions and/or myeloma proteins are the same as those for POEMS syndrome patients. In the absence of these features, treatment with rituximab , a monoclonal antibody preparation directed against B cells bearing the CD20 antigen, or siltuximab , a monoclonal ...
“The average myeloma patient, independent of race or ethnicity, sees their primary care provider three times with signs and symptoms that are consistent with myeloma before the diagnosis is ...
Ad
related to: life expectancy for myeloma patients symptoms and diagnosis